{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Groupes témoins : Questions médicales les plus fréquentes",
"headline": "Groupes témoins : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Groupes témoins : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Groupes témoins"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Méthodes",
"url": "https://questionsmedicales.fr/mesh/D008722",
"about": {
"@type": "MedicalCondition",
"name": "Méthodes",
"code": {
"@type": "MedicalCode",
"code": "D008722",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E05.581"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Groupes témoins",
"alternateName": "Control Groups",
"code": {
"@type": "MedicalCode",
"code": "D035061",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Steger-Hartmann",
"url": "https://questionsmedicales.fr/author/Thomas%20Steger-Hartmann",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany."
}
},
{
"@type": "Person",
"name": "Tania Rivera-Hernandez",
"url": "https://questionsmedicales.fr/author/Tania%20Rivera-Hernandez",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark J Walker",
"url": "https://questionsmedicales.fr/author/Mark%20J%20Walker",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre, The University of Queensland, St. Lucia, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Mark R Davies",
"url": "https://questionsmedicales.fr/author/Mark%20R%20Davies",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia."
}
},
{
"@type": "Person",
"name": "Alexander Gurjanov",
"url": "https://questionsmedicales.fr/author/Alexander%20Gurjanov",
"affiliation": {
"@type": "Organization",
"name": "Bayer Research & Development, Pharmaceuticals, Investigative Toxicology, Berlin, Germany. Electronic address: alexander.gurjanov@bayer.com."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A randomized controlled trial of a behavioral intervention for decreasing bedtime procrastination using a wait-list control group in a non-clinical sample of young adults.",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37354745",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.sleep.2023.06.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "Integrating non-concurrent controls in the analyses of late-entry experimental arms in multi-arm trials with a shared control group in the presence of parameter drift.",
"datePublished": "2022-10-25",
"url": "https://questionsmedicales.fr/article/36307007",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cct.2022.106972"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study protocol for a multi-center RCT testing a group-based parenting intervention tailored to mothers with borderline personality disorder against a waiting control group (ProChild*-SP1).",
"datePublished": "2022-07-23",
"url": "https://questionsmedicales.fr/article/35870944",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-022-06531-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Impact of SARS-CoV-2 Infection on Heart Rate Variability: A Systematic Review of Observational Studies with Control Groups.",
"datePublished": "2023-01-04",
"url": "https://questionsmedicales.fr/article/36673664",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20020909"
}
},
{
"@type": "ScholarlyArticle",
"name": "The effect of bariatric surgery in comparison with the control group on the prevention of comorbidities in people with severe obesity: a prospective cohort study.",
"datePublished": "2022-07-28",
"url": "https://questionsmedicales.fr/article/35902855",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12893-022-01740-7"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Techniques d'investigation",
"item": "https://questionsmedicales.fr/mesh/D008919"
},
{
"@type": "ListItem",
"position": 3,
"name": "Méthodes",
"item": "https://questionsmedicales.fr/mesh/D008722"
},
{
"@type": "ListItem",
"position": 4,
"name": "Groupes témoins",
"item": "https://questionsmedicales.fr/mesh/D035061"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Groupes témoins - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Groupes témoins",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Groupes témoins",
"description": "Comment identifier un groupe témoin ?\nQuel est le rôle d'un groupe témoin ?\nComment choisir un groupe témoin ?\nLes groupes témoins sont-ils toujours nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D035061?page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Groupes témoins",
"description": "Les groupes témoins montrent-ils des symptômes ?\nComment les symptômes sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061?page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Groupes témoins",
"description": "Les groupes témoins aident-ils à la prévention ?\nComment les groupes témoins influencent-ils la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D035061?page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Groupes témoins",
"description": "Quel type de traitement est comparé ?\nComment les résultats sont-ils mesurés ?",
"url": "https://questionsmedicales.fr/mesh/D035061?page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Groupes témoins",
"description": "Les complications sont-elles observées dans les groupes témoins ?\nComment les complications sont-elles analysées ?",
"url": "https://questionsmedicales.fr/mesh/D035061?page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Groupes témoins",
"description": "Les groupes témoins aident-ils à identifier des facteurs de risque ?\nComment les facteurs de risque sont-ils évalués ?",
"url": "https://questionsmedicales.fr/mesh/D035061?page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un groupe témoin ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un groupe témoin est constitué de participants similaires au groupe traité, mais sans intervention."
}
},
{
"@type": "Question",
"name": "Quel est le rôle d'un groupe témoin ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il permet d'évaluer l'effet d'un traitement en comparant les résultats avec ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Comment choisir un groupe témoin ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choix doit se baser sur des critères d'inclusion similaires à ceux du groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins sont-ils toujours nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils sont essentiels pour établir des comparaisons valides dans les études cliniques."
}
},
{
"@type": "Question",
"name": "Les groupes témoins montrent-ils des symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils ne reçoivent pas de traitement, donc ils ne présentent pas de symptômes liés au traitement."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils évalués ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes sont évalués par des questionnaires ou des examens cliniques dans les deux groupes."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à la prévention ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent d'évaluer l'efficacité des interventions préventives par comparaison."
}
},
{
"@type": "Question",
"name": "Comment les groupes témoins influencent-ils la prévention ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils fournissent des données sur l'impact des mesures préventives en comparaison avec l'absence d'intervention."
}
},
{
"@type": "Question",
"name": "Quel type de traitement est comparé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement expérimental est comparé à un placebo ou à un traitement standard dans le groupe témoin."
}
},
{
"@type": "Question",
"name": "Comment les résultats sont-ils mesurés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les résultats sont mesurés par des critères prédéfinis, comme l'amélioration des symptômes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles observées dans les groupes témoins ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent être observées, mais elles ne sont pas dues au traitement expérimental."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles analysées ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont analysées en comparant leur fréquence entre le groupe témoin et le groupe traité."
}
},
{
"@type": "Question",
"name": "Les groupes témoins aident-ils à identifier des facteurs de risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de comparer les facteurs de risque entre les groupes traité et témoin."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque sont-ils évalués ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont évalués par des questionnaires et des analyses statistiques dans les deux groupes."
}
}
]
}
]
}
Bedtime Procrastination (BP) is defined as the behavior of going to bed later than intended, without external reasons. This study is a randomized controlled trial aiming to establish efficacy of a beh...
This was an open-label trial that was conducted in sixty participants (mean age 21.33 ± 2.35 years, 86.7% females) without insomnia or psychopathology who endorsed frequent BP. They were randomized to...
The treatment group showed significant improvement on the BPS (35.56% decrease, d = 2.19, bedtime procrastination duration based on the sleep diary (-46.29 min, d = 1.22), and sleep efficiency (5.70% ...
This study shows promising results for a behavioral intervention targeting BP and sleep. In addition, this study demonstrated various functions of BP as a sleep-interfering behavior. We expect that th...
Under a master protocol, open platform trials allow new experimental treatments to enter an existing clinical trial. Whether late-entry experimental treatments should be compared to all available or c...
We explored the application of methods developed to incorporate historical controls in two-arm trials to the analysis of a late-entry arm in a simulated open platform trial under varying scenarios of ...
Simulated trial results confirm that in the presence of no drift, naively pooling all controls increases power and produces more precise, unbiased estimates when compared to using concurrent controls ...
Borderline personality disorder (BPD) is a severe mental disorder characterized by an unstable sense of self, intense and rapidly changing affect, as well as impulsive and self-destructive behaviors. ...
In a parallel-group, two-arm, randomized controlled trial, an initial N = 178 mothers diagnosed with BPD and their children aged 6 months to 6 years are assigned to either the parenting intervention o...
Mothers with BPD may need tailored help when reporting difficulties raising their children. The first disorder-specific parenting intervention has been developed to close this gap. ProChild is part of...
ClinicalTrials.gov NCT04169048 . Registered on Nov 19, 2019....
Autonomic nervous system (ANS) dysfunction can arise after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and heart rate variability (HRV) tests can assess its integrity. This ...
Obesity is a global health priority, particularly in developing countries. The preventive effect of bariatric surgery against obesity-related diseases in the developing countries of the Middle East an...
Severely obese participants who underwent bariatric surgery were compared with their counterparts who underwent no intervention. These patients had been followed up in two prospective cohort studies f...
In this study, 612 participants in the bariatric surgery group were compared with 593 participants in the control group. During the follow-up period, T2DM developed in eight (2.9%) people in the surge...
The risk reduction of obesity-related comorbidities after bariatric surgery should be considered in the decision-making process for public health in the region, which bariatric surgery could result in...
In experimental trials, new methods are tested against the "best" or "usual" care. To appraise control group (CG) interventions provided as "usual care," we focused on stroke as a leading cause of dis...
For this methodological appraisal, we conducted a systematic review of RCTs without timespan limitation. The PICO included stroke survivors, rehabilitation, control group intervention, lower limb func...
We included 155 publications. 13.6% of the articles did not describe the CG, and 11.6% indicated only the professionals involved. In the remaining 116 studies, three studies provided an intervention a...
This study shows that usual care in CG does not actually exist, as both specific terminology and consistency within CGP contents are missing. Reporting guidelines should give better assistance on this...
The substitution of an in-study control population with a historical control (HC) population is considered a viable option for reducing the necessary recruitment of control patients. However, it is ne...
For this case study, we re-evaluated data from a randomised, placebo-controlled trial using dienogest daily to treat EAPP with an HC arm based on data from a second randomised, placebo-controlled tria...
The difference between means (placebo minus treatment) in change in pain, as measured on the Visual Analogue Scale from baseline to end of treatment, deviates in the comparison treatment/pool of HC (7...
Using HC with PS matching has proven to be useful in the setting of treating EAPP, while emphasis must be given to the selection mechanism and the underlying assumptions. This case study has shown tha...
NCT00225199, NCT00185341....
There is limited data on the prevalence and risk factors for long COVID and few prospective studies with appropriate control groups and adequate sample sizes. We performed a prospective study to deter...
We recruited individuals aged ≥15 years who were clinically suspected of having an acute SARS-CoV-2 infection from September 2020 to April 2021. We collected nasopharyngeal swabs three to five days fo...
We followed 814 participants (412 COVID-19 positive and 402 COVID-19 negative persons). Most (n = 741/814) had mild symptoms. Both groups had similar sociodemographic and clinical characteristics, exc...
In this prospective study consisting predominantly of individuals with mild disease, the persistence of symptoms after an acute respiratory illness was associated with a diagnosis of COVID-19. Polysym...
Adenoma detection rate (ADR) is still the main surrogate outcome parameter of screening colonoscopy, but most studies include mixed indications, and basic ADR is quite variable. We therefore looked at...
Patients in the control groups of randomized controlled trials (RCTs) on ADR increase using various methods were collected based on a systematic review; this control group had to use high-definition w...
From 80 studies, 25,304 patients in the respective control groups were included. ADR in control arms varied between 8.2% and 68.1% with a high degree of heterogeneity (I...
A high level of variability was found in the level of ADR in the control groups of RCTs. With regards to indications, only fecal immunochemical test-based colonoscopy studies influenced basic ADR, and...
Assess the incidence and factors associated with major depressive episodes (MDEs) and symptoms of depression and anxiety during pregnancy and postpartum periods in pregnant women with epilepsy (PWWE) ...
The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs study is a multicenter NIH-funded prospective observational parallel group cohort study of PWWE and their children. This rep...
This study included PWWE (n = 331) and HPW (n = 102) during pregnancy and postpartum and NPWWE (n = 102) at comparable times. No difference in SCID-diagnosed MDE incidence was found across groups, but...
Although SCID-based MDE did not differ across groups, this prospective study confirms higher rates of psychiatric symptoms in patients with epilepsy during pregnancy and postpartum, provides new data ...
This study is registered at ClinicalTrials.gov as NCT01730170....